Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion

Description

Summary

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

Official Title

A Phase II, Open-Label, Multicenter, Randomized Study Of The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab In Patients With Previously Untreated Advanced Melanoma

Keywords

Advanced Melanoma Melanoma Pembrolizumab

Eligibility

You can join if…

Open to people ages 18 years and up

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Life expectancy >= 12 weeks
  • Adequate hematologic and end organ function
  • Naive to prior systemic anti-cancer therapy for advanced melanoma, with the exceptions as specified in the protocol
  • Tumor specimen availability
  • Measurable disease per RECIST v1.1

You CAN'T join if...

  • Ocular or acral melanoma
  • Any anti cancer therapy with the exceptions as specified in the protocol
  • Symptomatic, untreated, or actively progressing CNS metastases
  • Previous splenectomy
  • History of autoimmune disease
  • Prior allogeneic bone marrow transplantation or prior solid organ transplantation
  • Positive test for Human Immunodeficiency Virus (HIV) infection
  • Active hepatitis B or C or tuberculosis
  • Significant cardiovascular disease
  • Known clinically significant liver disease

Locations

  • UCSF Comprehensive Cancer Ctr not yet accepting patients
    San Francisco California 94115 United States
  • The Angeles Clinic accepting new patients
    Los Angeles California 90025 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Genentech, Inc.
ID
NCT03815058
Phase
Phase 2
Study Type
Interventional
Last Updated